We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verseon (DI) | LSE:VSN | London | Ordinary Share | COM USD0.001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 74.00 | 70.00 | 78.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVSN
RNS Number : 2206N
Verseon Corporation
07 August 2017
August 7, 2017
Verseon Corporation
("Verseon" or the "Company")
Additional Listing & Total Voting Rights
Verseon, a technology-based pharmaceutical company, announces that application has been made for 22,425 new Common Shares of par value $0.001 each (the "Common Shares") to be admitted to trading on AIM pursuant to the exercise of options and the regularly scheduled vesting of restricted stock units (the "Issuance").
The 22,425 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on August 10, 2017.
Total Voting Rights
Following the Issuance, the issued share capital of the Company will consist of 151,475,316 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 151,432,399. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact
Verseon Corporation www.verseon.com +1 (510) 225 Tina Schlafly 9000 Cenkos Securities (NOMAD and Joint Broker) +44 (0) 20 Neil McDonald / Beth McKiernan 7397 8900 Cantor Fitzgerald Europe (Joint Broker) Marc Milmo / Phil Davies / +44 (0) 20 Callum Butterfield 7894 7000 Mirabaud Securities LLP (Joint Broker) +44 (0) 20 Peter Krens 7321 2508
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers) Henry Harrison-Topham / Henry +44 (0) 20 Wilson 7466 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts +44 (0) 1737 Simon Vane Percy 821 890
-
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUNAURBNAWRUR
(END) Dow Jones Newswires
August 07, 2017 02:00 ET (06:00 GMT)
1 Year Verseon Chart |
1 Month Verseon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions